Please ensure Javascript is enabled for purposes of website accessibility

Should I Sell Moderna Shares?

By Eric Volkman – Jun 25, 2020 at 4:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's stock has taken off like a rocket this year thanks to mRNA-1273, which thus far appears to be one of the more promising COVID-19 vaccine candidates.

Moderna (MRNA -3.19%) is a white-hot COVID-19 stock just now. Onlookers have high hopes for mRNA-1273, the company's SARS-CoV-2 vaccine candidate, which is progressing rapidly through the development process. It's now well into phase 2 clinical testing, and the company has been given FDA approval to start a phase 3 study next month.

Many investors, it seems, are betting that the vaccine candidate will not only be successful, but successful early enough to garner a significant first-mover advantage. Given that nearly every rational human being on Earth will want and need vaccination against COVID-19, that market is set to be unimaginably massive.

It's an exciting possibility for Moderna, but investors have to bear a few things in mind once the dream wears off.

Businessman and businesswoman glancing at a screen to consider a decision.

Image source: Getty Images.

Firstly, as ever in the biotech world, we can't know if mRNA-1273 will ultimately prove efficacious. On top of that, Moderna is one of many companies and organizations working overtime to develop vaccines and treatments for COVID-19. Even mRNA-1273 works well enough to meet the requirements for a vaccine, other attempts could prove more effective, leaving Moderna at a disadvantage.  

Some of its rivals in this competition also have significant financial firepower, buttressed (like Moderna) by recent inflows of both public and private funds disbursed to aid the fight against the disease. A number also have global reach and a wide network of partners; I'm thinking in particular of Novavax and AstraZeneca, as well as pharmaceutical giants Pfizer and Merck.

So the decision whether to sell comes down to how much you, as an investor, rate Moderna's chances in this crowded race -- a race in which early leads can fade, and not every competitor will even cross the finish line.

If you feel mRNA-1273 has a good shot at not only sailing through its clinical trials and getting enough runway to be the COVID-19 vaccine for a good stretch of time, I'd say you should hold on to the stock. Otherwise, if you bought early, consider unloading at least some of your position and banking your considerable share price gains.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$119.69 (-3.19%) $-3.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.